<DOC>
	<DOC>NCT02444221</DOC>
	<brief_summary>To discover outcomes of patients treated with Rivaroxaban with atrial fibrillation with at least one additional investigator-determined risk factor for stroke in real-life practice.</brief_summary>
	<brief_title>Rivaroxaban Evaluation in Real Life Settings</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Written informed consent Age 18 years and over New diagnosis of nonvalvular atrial fibrillation (diagnosed within the last 6 weeks) with at least one additional investigatordetermined risk factor for stroke and regardless of therapy No further followup envisaged or possible within enrolling hospital or with associated family practitioner. Patients with transient AF secondary to a reversible cause. According to the European Directive 2001/20/EC, patients recruited in controlled clinical trials are not eligible for registries</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Stroke</keyword>
</DOC>